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Cardiac preconditioning is mediated by protein kinase C. Although endoge- 
nous calcium is a potent stimulus of protein kinase C, it remains unknown 
whether preischemic administration ofexogenous calcium can induce protein 
kinase C-mediated myocardial protection against ischemia-reperfusion injury. 
To study this, calcium chloride was administered retrogradely through the 
aorta at a rate 5 nmol/min for 2 minutes to isolated perfused rat hearts 10 
minutes before a 20-minute ischemia and 40-minute reperfusion insult. 
Calcium-mediated cardioadaptation was then linked to protein kinase C by 
means of the protein kinase C inhibitor chelerythrine (20 /xmol .L -1.2 
min-1). To determine whether exogenous calcium administration i duces 
protein kinase C translocation and activation, immunohistochemical st ining 
for the calcium-dependent protein kinase C isoform a was performed on 
adjacent 5 pm myocardial sections with and without calcium chloride treat- 
ment. Results indicated that preischemic alcium chloride administration 
improved myocardial functional recovery, as determined by enhanced evel- 
oped pressure, improved coronary flow, reduced end-diastolic pressure, and 
decreased creatine kinase leakage during reperfusion. Beneficial effects of 
calcium chloride were eliminated by concurrent protein kinase C inhibition. 
Immunohistochemical st ining for the a isoform of protein kinase C demon- 
strated that calcium chloride induces translocation of this isoform from the 
cytoplasm to the sarcolemma, indicating that exogenous calcium administra- 
tion activates this isoform. These results suggest that calcium chloride, a safe 
and routinely administered agent, can induce protein kinase C-mediated 
cardiac preconditioning. Calcium-induced cardioadaptation to ischemia 1 
reperfusion injury may be promising as a clinically feasible therapy before 
planned ischemic events such as cardiac aIlograft preservation and elective 
cardiac operations. (J Thorac Cardiovasc Surg 1996;112:778-86) 
C ardiac preconditioning, first termed "ischemic preconditioning," confers myocardial protection 
against ischemia-reperfusion injury. 1-11 Several ap- 
parently disparate stimuli, including adenosine, nor- 
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epinephrine, and bradykinin, simulate the protective 
effects of ischemic preconditioning. 1-4' 7, 10 Although 
cardiac preconditioning with either ischemia or 
pharmacologic agents is possible in animal models, 
clinical application has been limited for two reasons: 
(1) ischemic preconditioning stimuli are clinically 
unappealing, and (2) cardiac preconditioning re- 
quires planned ischemic events. Elective cardiac 
operations and heart transplantation may represent 
the extent of cardiac preconditioning's clinical ap- 
plication. 
The protective ffects of different cardiac precon- 
ditioning stimuli appear to rely on protein kinase C 
(PKC) as a common intracellular effector. 3'4' 11-1s 
Indeed, we 3 and others 11' 12 have directly activated 
PKC with phorbol esters and diacylglycerol, simu- 
lating the protection afforded by ischemic precondi- 
tioning.3, ~1, 12 Calcium is an important endogenous 
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activation stimulus of calcium-dependent PKC iso- 
forms (cPKC). 16 It is unknown whether the admin- 
istration of exogenous calcium chloride (CaC12), 
which is both relatively safe and routinely adminis- 
tered clinically, can induce PKC-mediated myocar- 
dial functional protection. To study this, exogenous 
CaC12 was administered as a preconditioning stim- 
ulus before ischemia-reperfusion to determine the 
following: (1) whether preischemic CaC12 adminis- 
tration can induce endogenous myocardial func- 
tional protection, (2) whether CaC12 reduces myo- 
cellular damage (as marked by creatine kinase [CK] 
leakage), (3) whether CaC12 results in translocation 
and activation of the oz cPKC isoform (o~PKC), and 
(4) whether CaC12-induced myocardial protection is 
mediated by PKC. 
Materials and methods 
Materials. Male Sprague-Dawley rats (weight 325 to 
350 gin; Saseo, Omaha, Neb.) were fed a standard iet and 
acclimated in a quiet quarantine room for 2 weeks before 
the experiments. The animal protocol was reviewed and 
approved by the Animal Care and Research Committee of 
the University of Colorado Health Sciences Center. All 
animals received humane care in compliance with the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Institute of Laboratory Animal 
Resources and published by the National Institutes of 
Health (NIH publication No. 86-23, revised 1985). The 
PKC inhibitor chelerythrine was obtained from L C 
Laboratories (Woburn, Mass.). Antibody to aPKC was 
obtained from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, Calif.). All other chemicals and reagents were 
obtained from Sigma Chemical Co. (St. Louis, Mo.). 
Experimental design and groups. Each ischemia-reper- 
fusion experiment totaled 80 minutes, beginning with a 
mandatory equilibration period. Stability control hearts 
(with and without 0.25 mmol/L CaC12 and 20 ~mol/L 
chelerythrine treatment) underwent 80 minutes of oxy- 
genated perfusion without any ischemia to ensure prepa- 
ration stability. Injury control hearts were perfused for 8 
minutes (equilibration) and then received 2-minute infu- 
sions of each respective vehicle, followed by a 10-minute 
washout period, and a standard ischemia-reperfusion in- 
sult (20 minutes of 37 ° C global ischemia nd 40 minutes 
of reperfusion). CaClz-treated hearts received 8 minutes 
of perfusion followed by a 2-minute retrograde aortic 
infusion of CaCI2 at 5 nmol/min for 2 minutes (based on 
a 20 ml/min coronary flow [CF] rate). This was followed by 
a 10-minute washout period of standard perfusion. The 
CaC12 dose was based on dose-response curves generated 
in our laboratory, which demonstrated that this dose 
provided optimal protection compared with both higher 
and lower doses. To determine whether the observed 
protective ffects of CaC12 were mediated by PKC, the 
PKC inhibitor chelerythrine was administered with and 
without CaC12 after equilibration, 10 minutes before the 
standard ischemia-reperfusion protocol. All drug solu- 
tions were prepared in deionized water and infused 
through a port above the aortic root at 0.1 ml/min (not 
recirculated). Hemodynamic parameters were continu- 
ously recorded before, during, and after infusion. 
Ischemia-reperfusion of the isolated rat heart: devel- 
oped pressure (DP), end-diastolic pressure (EDP), CF, 
and heart rate measurements. The isolated, crystalloid- 
perfused rat heart model described elsewhere was 
used.2-4, 17, 18 In brief, after anesthesia and heparinization 
(60 mg/kg intraperitoneal sodium pentobarbital nd 500 
units intraperitoneal heparin sodium) hearts were excised 
into 4°C Krebs-Henseleit solution and perfused with 
oxygenated buffer within 45 seconds. Hearts were retro- 
gradely perfused in the isolated, isovolumetric Langen- 
dorff mode (70 mm Hg) with modified Krebs-Henseleit 
solution (5.5 mmol/L glucose, 1.2 mmol/L calcium ion 
[Ca2+], 4.7 mmol/L potassium chloride, and 25.0 mmol/L 
sodium bicarbonate) and saturated with 92.5% oxygen 
and 7.5% carbon dioxide atmosphere to achieve an oxy- 
gen tension of 440 to 460 mm Hg, a carbon dioxide 
tension of 39 to 41 mm Hg, and a pH of 7.39 to 7.41 
(ABL-4 blood gas analyzer; Radiometer Medical A/S, 
Copenhagen, Denmark). Pulmonary arteriotomy and left 
atrial resection were performed before insertion of a 
water-filled latex balloon through the left atrium into the 
left ventricle. The balloon was then adjusted to a left 
ventricular EDP of 6 mm Hg during the initial equilibra- 
tion. This preload volume was held constant during the 
entire experiment to allow continuous recording of the 
ventricular pressure during ischemia-reperfusion. Pacing 
wires were fixed to the right atrium and pulmonary 
outflow tract and hearts were paced at approximately 6 Hz 
(355 beats/min) for 1 minute to ensure a standardized 
heart rate during the time points at which DP was 
measured. During the remainder of the experiments, the 
pacer was off. A unipolar electrocardiogram was obtained 
through alead placed on either the right or left ventricular 
free wall to allow continuous recording of an electrocar- 
diographic signal. 
Measured indexes of myocardial function were left 
ventricular DP, EDP, CF, and native heart rate. Data 
were continuously recorded with a computerized MacLab 
8 preamplifier/digitizer (AD Instruments Inc., Milford, 
Mass.) and an Apple Quadra 800 computer Inc., Cuper- 
tino, Calif.). The electrocardiographic signal was ampli- 
fied with a DP-301 differential amplifier (Warner Instru- 
ment Corp., Hamden, Colo.) and digitized at 400 Hz on 
the MacLab 8 preamplifier/digitizer. Paced hearts that did 
not produce 105 _+ 25 mm Hg DP at 6 mm Hg EDP were 
discarded. A three-way stopcock above the aortic root was 
used to create global ischemia, during which time the 
heart was placed in a 37 ° C degassed organ bath. CF was 
measured in graduated cylinders at the end of equilibra- 
tion, immediately after drug infusion, and at the end of 
reperfusion. At 10, 20, 30, and 40 minutes of reperfusion, 
i ml coronary effluent was collected and frozen at -70 ° C. 
Coronary effluent CK activity was determined within 2 
weeks. 
Coronary effluent CK activity. Coronary effluent (1 ml) 
was collected at 10, 20, 30, and 40 minutes of reperfusion 
and then frozen at -70°C until assay. All assays were 
performed within 2 weeks of effluent collection. The assay 
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was performed with Sigma diagnostic kit no. 47-UV on an 
automated spectrophotometer (Centrifichem 500 discrete 
autoanalyzer; Union Carbide Chemicals & Plastics Co. Inc., 
Bound Brook, N.J.) in cuvettes maintained at 37 ° C. Samples 
and reagents were maintained at 4 ° C before assay. Solutions 
were prepared in distilled, deionized water. Results are 
presented as CK activity in units per liter. 
Subcellular localization of aPKC. Myocardial subcel- 
lular localization of the c~PKC was performed with immu- 
nofluorescence staining. These hearts were obtained im- 
mediately after 2-minute CaC12 infusion (0.25 mmol/L) in 
CaClz-treated hearts and after 10-minute quilibration i
control hearts. Ventricular tissue was excised from iso- 
lated beating hearts, blotted, embedded in tissue-freezing 
medium, rapidly frozen in dry ice-cooled 2-methylbutane, 
and stored at -70 ° C. Transverse 5 ixm cryosections were 
prepared with a cryostat (2800 Frigocut E; Reichert-Jung, 
Germany) and collected on slides coated with poly-L- 
lysine. All sections were fixed for 10 minutes in a 70% 
acetone-30% methanol mixture at -20 ° C. Normal goat 
serum (5% in phosphate-buffered saline solution [PBS] 
and 5% normal sheep serum) was applied as a blocking 
agent and washed three times in PBS for 3 minutes. 
Sections from the experimental groups were then incu- 
bated for 1 hour with diluted primary antibody (rabbit 
polyclonal antibody against c~PKC) at room temperature 
with mouse antisarcomeric a-actin antibody. For all 
groups, individual PKC isoform staining was performed 
on adjacent sections. After the sections were washed three 
times with PBS for 3 minutes, they were incubated with 
Cy-3 conjugated goat antirabbit IgG for 45 minutes. 
During this step, sections were also exposed to antisarco- 
meric a-actin antibody coincubated with fluorescein iso- 
thiocyanate-conjugated sheep antimouse immunoglobu- 
lin G antibody. Sections were then washed three times 
with PBS for 3 minutes. Slides were mounted with a 
glycerol-based antiquenching agent (O-phenylene dia- 
mine-D:HC1) and stored at 4 ° C. To test for nonspecific 
fluorescence, adjacent sections of each experimental group 
were incubated with nonimmune purified rabbit immuno- 
globulin G instead of primary antibodies. Sections were 
viewed and photographed with a microscope quipped with 
fluorescence optics (Axioskop with MC-100 camera; Carl 
Zeiss, Oberkochen, Germany). Multiple sections per heart 
were examined. Three different hearts were examined per 
group. Representative s ctions are presented. 
Presentation of data and statistical analysis. All re- 
ported values are mean (-+ standard error of the mean, 
n = 6 to 8 per group). Differences at the 95% confidence 
level were considered significant. Functional recover- 
ies--DP (in millimeters of mercury), left ventricular EDP 
(in millimeters of mercury), CF (in milliliters per minute), 
heart rate (in beats per minute), and CK activity (in units 
per liter)--were compared at the corresponding time 
points between groups with one-way analysis of variance 
with post hoc Bonferroni-Dunn test (StatView 4.0; Aba- 
cus Concepts, Inc., Berkeley, Calif.). 
Results 
Twenty minutes of normothermic (37 ° C) global 
ischemia was chosen as the ischemia-reperfusion insult 
because this reproducibly establishes a 50% decrease 
in functional recovery of untreated hearts, z-< 17-19 Fi- 
nal function in CaClz-pretreated hearts was greater 
than 75%, which provided a dynamic range within 
which cardiac functional protection could be studied. 
Stability control hearts for vehicle, CaC12, and 
chlerythrine-treated h arts retained more than 95% of 
baseline DP, heart rate, and CF. 
Effects of CaCI 2 pretreatment, with and without 
concurrent PKC inhibition, on DP. The effect of 
preischemia CaC12 on DP after ischemia-reperfu- 
sion was explored in a manner similar to that in 
previous regional and global ischemia isolated rat 
heart models. 2-4' 17-19 DP did not differ between the 
groups during equilibration and measured 112 _+ 9, 
113 _+ 7, 117 _+ 8, and 115 +_ 7 mm Hg in the control, 
CaCl2, CaC12 plus chelerythrine, and chelerythrine 
groups, respectively (Fig. 1). After agent or vehicle 
administration, DP increased transiently in the 
CaC12 and the CaC12 plus chelerythrine groups to 
124 + 9 and 125 _+ 8 mm Hg, respectively. DP did 
not change after vehicle (control) or chelerythrine 
administration alone. After washout, DP returned 
to baseline in all groups. At 40 minutes of reperfu- 
sion, DP was increased in the CaC12 group (89 _+ 
6.1) with respect to control, CaCI2 plus chelery- 
thrine, and chelerythrine groups, which measured 
60.2 + 6.8, 69 _+ 9, and 58 +_ 7, respectively (p < 
0.05). 
Effects of CaCI 2 pretreatment, with and without 
concurrent PKC inhibition, on CF. The effect of 
preischemia CaC12 on CF after ischemia-reperfu- 
sion is shown in Fig. 2. During equilibration, CF did 
not differ among the groups and measured 20 _+ 1.2, 
20.5 _ 1.6, 20.4 _+ 1.5, and 19.8 +_ 1.4 ml/min in the 
control, CaC12, CaCI 2 plus chelerythrine, and chel- 
erythrine groups, respectively. After agent or vehicle 
administration, CF increased transiently in the 
CaC12 and the CaC12 plus chelerythrine groups to 
22 _+ 1.4 and 21.8 -+ 1.4 ml/min, respectively. CF did 
not change after vehicle (control) or chelerythrine 
administration alone. After washout, CF returned to 
baseline in all groups. At 40 minutes of reperfusion, 
CF was increased in the CaC12 group (17.5 _+ 1.2 
ml/min) with respect to the control, CaC12 plus 
chelerythrine, and chelerythrine groups, which mea- 
sured 12 _ 1.8, 13 - 2, and 12.5 +_ 1.2 ml/min, 
respectively (p < 0.05). 
Effects of CaCI 2 pretreatment, with and without 
concurrent PKC inhibition, on EDP after ischemia 
and during reperfusion. CaC12 pretreatment de- 
creased EDP after ischemia-reperfusion from 46 _ 
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Fig. 1. Effect of preischemic administration f CaC12, with and without PKC inhibition, on myocardial DP 
during ischemia-reperfusion. During equilibration, DP averaged approximately 110 mm Hg in all groups. 
After agent or vehicle administration, there was a transient increase in DP in CaC12 and CaC12 plus 
chelerythrine (Chel) groups; DP rapidly returned to baseline after the 2-minute infusion. During ischemia, 
DP decreased to 0 mm Hg in all groups. During reperfusion, DP recovery of CaC12-treated group was 
increased with respect to control, CaC12 plus chelerythrine, and chelerythrine groups, n = 6 to 8 per group. 
Equil, Equilibration. 
6 to 29 _+ 4 mm Hg (p < 0.05; Fig. 3). After PKC 
inhibition with chelerythrine, the EDP of CaC12- 
treated hearts was similar to that of ischemia- 
reperfusion control hearts, 43 _+ 3 mm Hg (p < 0.05 
vs CaC12). Chelerythrine infusion alone did not 
result in any additional increase in EDP compared 
with ischemia-reperfusion alone, 47 _+ 4.3 mm Hg 
(p < 0.05 vs CaC12). 
Efect of CaCI 2 pretreatment, with and without 
concurrent PKC inhibition, on coronary effluent CK 
activity. CK activities in coronary effluents (CK 
leakage) were determined at 10, 20, 30, and 40 
minutes of reperfusion and are shown in Fig. 4. At 
10 minutes of reperfusion, coronary effluent CK 
activities were 58.02 + 10.5, 38.92 _+ 8.6, and 
56.79 _+ 12.75 U/L in the control, CaCI2, and CaC12 
plus chelerythrine groups, respectively. At 20 min- 
utes of reperfusion, coronary effluent CK activities 
were 59.55 + 9.74, 45.78 + 7.45, and 72.64 _+ 8.6 
U/L in the control, CaC12, and CaC12 plus cheleryth- 
rine groups, respectively (p < 0.05 CaC12 vs CaC12 
plus chelerythrine). At 30 minutes of reperfusion, 
the CK leakage of the CaCla-treated group was less 
than those in both CaC12 plus chelerythrine and 
control groups, measuring 29.77 _+ 8.4 versus 57.87 
_+ 11.56 and 67.8 _+ 11.1 U/L, respectively (p < 0.05 
vs control and CaC12 plus chelerythrine). At 40 
minutes of reperfusion, the CK leakage of the 
CaClz-treated group was less than those in both 
CaC12 plus chelerythrine and control groups, mea- 
suring 19.69 _+ 7.4 versus 52.65 _+ 9.2 and 54.18 _+ 
7.6 U/L, respectively (p < 0.05 vs control and CaC12 
plus chelerythrine). Chelerythrine treatment alone 
did not affect CK leakage compared with the control 
group. At 10, 20, 30, and 40 minutes of reperfusion, 
the CK leakages in the chelerythrine-treated group 
measured 62.4 _+ 7.6, 56.72 _+ 8.2, 54.2 + 9.7, and 
47.6 _+ 7.4 U/L, respectively. 
Effect of CaCl 2 on ozPKC translocation. Translo- 
cation of PKC from cytosolic to particulate compart- 
ments is commonly used as an index of activa- 
tion.3,4, 16 Indirect immunofluorescent microscopy 
was used to verify CaZ+-induced activation of the 
calcium-dependent oLPKC. Although this technique 
primarily provides qualitative data, the use of iso- 
form-specific anti-PKC antibodies allows the assess- 
ment of both isoform-selective activation and com- 
partmentalization. Fig. 5 (A) demonstrates control 
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Fig. 2. Effect of preischemic administration f CaC12, with and without PKC inhibition, on CF during 
ischemia-reperfusion. During equilibration, CF averaged approximately 20 ml/min in all groups. After agent or 
vehicle administration, there was a transient increase in CF in CaC12 and CaC12 plus chelerythrine (Chel) 
groups; CF rapidly returned to baseline after the 2-minute infusion. During ischemia, CF decreased to0 ml/min 
in all groups. During repeffusion, CF recovery of the CaC12-treated group was increased with respect to control, 
CaC12 plus chelerythrine, and chelerythrinc groups, n = 6 to 8 per group. Equil, Equilibration. 
heart sections with diffuse cytoplasmic distribution 
of ozPKC; after CaC12 treatment, however, aPKC 
translocates to the sarcolemma (Fig. 5, B). Results 
represent multiple sections from three different 
hearts per group. 
Discussion 
Ischemic preconditioning has emerged as a means 
of inducing endogenous myocardial protection after 
ischemia-reperfusion injury. 1-4'9'12-14 The protec- 
tive effects of different cardiac preconditioning stim- 
uli appear to rely on PKC as a common intracellular 
effector.3,4, 11-15 Ca2+ is an important endogenous 
activation stimulus of cPKC. 16 Although increased 
intracellular Ca 2+ concentration ([Ca2+]i) repre- 
sents the final common denominator f cell dysfunc- 
tion and death after ischemia-reperfusion, s' 9, 20-29 it 
is possible (although counterintuitive) that a pre- 
ischemic Ca 2+ stimulus might incite endogenous 
events that culminate in myocardial protection 
against ischemia-reperfusion. A calcium stress thus 
may provide cardioprotection, analogous to tran- 
sient ischemic preconditioning, against sustained 
ischemia-reperfusion. Steenbergen and coworkers 9 
have demonstrated that ischemic preconditioning 
limits alterations in various intramyocellular ions 
after ischemia-reperfusion. Ischemic precondition- 
ing therefore appears to induce, or alternatively to 
"prime," the cellular machinery required to main- 
tain ion homeostasis during a subsequent ischemic 
episode. These beneficial effects appear to explain, 
at least in part, preconditioning's protective ffects. 
Although the intermediaries have yet to be com- 
pletely elucidated, PKC activation is required for all 
preconditioning stimuli examined to date. 3'4' 11-~4 
Indeed, direct PKC activation with phorbol esters 
and diacylglycerol results in functional and viability 
protection after ischemia-reperfusion. 3' 11,12 Al- 
though [Ca2+]i is an important endogenous activa- 
tor of PKC, it is unknown whether exogenous Ca 2+, 
a clinically accessible and acceptable stimulus, can 
activate PKC and thereby induce myocardial func- 
tional protection. 
Our observations suggest hat exogenous CaC12 
administration can induce PKC-mediated myocar- 
dial functional protection. Exogenous CaC12 admin- 
istration before ischemia-reperfusion mproved DP 
(Fig. 1) and CF (Fig. 2) after ischemia-reperfusion 
and decreased EDP (Fig. 3) and CK leakage (Fig. 4) 
after ischemia-reperfusion. Furthermore, PKC inhi- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 3 
Meldrum et al. 78 3 
70- 
60" 
40' 
:  ontro 
30' [] CaC12 
.~ CaC12+Chel 
o Chel *P<0.05 vs Control 
20 , ~ , , 
0 10 20 30 40 
Time (min) Into Reperfusion 
Fig. 3. Effect of preischemic administration of CaC12, with and without PKC inhibition, on EDP during 
reperfusion. After 20 minutes of ischemia, EDP was 57 mm Hg in the control group; EDP decreased to 
approximately 45 mm Hg after 40 minutes of reperfusion. CaC12 pretreatment decreased postischemic 
EDP to 38 mm Hg, which decreased further to 29 mm Hg after reperfusion. PKC inhibition with 
chelerythrine (Chel) abolished CaClz-induced protective ffects (Ca CI 2+ Chel). Chelerythrine alone did not 
result in any additional injury when administered before an indentical ischemia-reperfusion insult, n - 6 
to 8 per group. 
bition with chelerythrine abolished these effects 
(Figs. 1 through 4), thus implicating PKC activation 
in the mechanism of CaC12-induced protective f- 
fects. Further substantiating the hypothesis that 
CaC12 can induce PKC-mediated myocardial func- 
tional protection is the observation that CaC12 re- 
sults in aPKC translocation to the sarcolemma (Fig. 
5). Because c~PKC was the only isoform examined, it
is possible that other isoforms inhibited by chel- 
erythrine are involved. The translocation of this 
isoform may be coincidental, and not responsible for 
the protection observed. Indeed, different precondi- 
tioning stimuli may effect preconditioning through 
the activation of different isoforms. 3'4 Nevertheless, 
Ca 2+ preconditioning was indeed prevented by con- 
current PKC inhibition. It is of interest that the 
improved functional recovery observed is derived al- 
most entirely from a reduction in EDP, without appre- 
ciable increase in systolic pressure. This suggests that 
the protective ffects may be caused by reduction of 
irreversible injury, rather than of stunning. 
Brief ischemia can itself condition the heart against 
a more prolonged ischemic insult. 1-3'7,9, 10,12 In an 
effort to analyze the mechanisms of ischemia-induced 
functional protection, several investigators established 
a role for ischemic stress hormones 2'4'24'3°'31 and 
suggested a role for [CaZ+]i.*). Ashraf and coworkers 2°
focused on manipulating the extracellular Ca 2+ con- 
centration ([Ca2+]o) and report that exposing the 
heart to a transient depletion and repletion of Ca 2+ 
protects the cell against a subsequent, more severe 
depletion and repletion of Ca 2+ (calcium paradox). 
Calcium paradox injury indeed approximates the dam- 
age inflicted during ischemia-reperfusion injury. It 
therefore seemed possible that a preischemic Ca 2+ 
stimulus would also provide functional protection 
against ischemia-reperfusion njury. The mechanisms 
by which an antecedent s ress (ischemia, stress hor- 
mones, or elevated [Ca2+]i) results in cardioadaptation 
to a subsequent insult are only beginning to be eluci- 
dated; however, PKC appears to act as a common 
intracellular effeetor. 3'4, 12, 14, 15 
The signal transduction cascades of a large num- 
ber of receptors are linked to PKC. 16 Consequently, 
many different stimuli that activate PKC could the- 
oretically lead to cardiac functional protection 
*References 3, 4, 8, 9, 14, 15, and 20. 
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Fig. 4. Effect of preischemic administration of CaC12, with and without PKC inhibition, on CK leakage 
during reperfusion. At 10, 20, 30, and 40 minutes of reperfusion, 1 ml coronary effluent was collected and 
assayed for CK activity in all groups. At 10 minutes of reperfusion, CK activity in the CaC12 group averaged 
approximately 40 U/L, whereas CK activity in control, CaC12 plus chelerythrine (Chel), and chelerythrine 
groups averaged approximately 60 U/L. At 20 minutes of reperfusion, CK activities were similar to those 
at the 10-minute time point for each group. At 30 and 40 minutes of reperfusion, CK leakage decreased 
in the CaC12 group to approximately 20 U/L by 40 minutes of reperfusion, different from both control and 
CaC12 plus chelerythrine groups, which both averaged approximately 55 U/L at 40 minutes of reperfusion 
(p < 0.05). n = 6 to 8 per group. 
against ischemia-reperfusion njury. Indeed, tran- 
sient ischemic, purinergic, and aa adrenergic stimuli, 
all of which provide myocardial functional protec- 
tion, appear to act in common through PKC.* PKC 
regulates intracellular processes both by direct phos- 
phorylation and by initiating the induction of other 
protein kinase cascades. 16Multiple extracellular nd 
intracellular ischemia-responsive stimuli may pro- 
vide common communication byPKC. Direct PKC 
activation induces myocardial functional protection, 
and PKC inhibition can block this protection. 3' 12,14 
Endogenous [Ca2+]i is an important activator of 
PKC, 16 and elevation of [Ca2+]i is also coincident 
with the action of these ischemic stress stimuli32; 
however, it is unknown whether exogenous Ca 2+ 
administration can activate PKC and thereby induce 
myocardial functional protection similar to that 
observed after ischemic preconditioning. Our data 
suggest that preischemic CaC12 administration can 
induce functional protection after ischemia-reperfu- 
*References 1, 3, 4, 7, 12, 15, and 30. 
sion and limit myocellular CK leakage by means of 
a PKC-dependent mechanism. 
The exact mechanism by which PKC provides 
myocardial functional protection is unknown. Be- 
cause PKC translocation and activation appear to be 
central to the functional protection afforded by 
several different stimuli, it is possible that PKC 
translocation to various intracellular sites regulates 
upward the cellular machinery required to adapt o 
the ensuing ischemia-reperfusion insult. For exam- 
ple, translocation of PKC to the sarcolemma may 
signify the priming of cellular machinery at this 
location; phosphorylation a d activation of the so- 
dium ion-hydrogen ion exchanger or sodium ion- 
Ca 2+ exchanger may prepare the art to better 
regulate ion gradients after ischemia-reperfusion. 
Similarly, sarcoendoplasmic reticulum Ca 2÷ adeno- 
sine triphosphatase activity may be upregulated, 
allowing the heart o adapt o the subsequent Ca 2+ 
load associated with ischemia-reperfusion njury. 
This, however, remains to be determined. Indeed, 
precond ming's link with PKC may only be an 
A 
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Fig. g. Immunohistofluorescence images of PKC translocation after CaC12 treatment; ransverse 5 /xm 
cryosections of rat heart incubated with rabbit polyclonal antibody against aPKC. A, Control heart 
incubated with rabbit polyclonal antibody against c~PKC demonstrates diffuse cytoplasmic staining (original 
magnification ×63). B, CaC12-treated heart incubated with rabbit polyclonal ntibody against c~PKC 
demonstrates translocation f this isoform to the sarcolemma ( rrows) from the cytoplasm, suggesting that
exogenous CaC12 administration activates c@KC (original magnification x63). 
association. Although PKC may be operative in some 
forms of preconditioning, other kinases may be oper- 
ative after other preconditioning stimuli. It is therefore 
possible according to the work of Asimakis and 
Conti, 31 that Ca 2+ preconditioning is independent of
PKC. These authors reported that dobutamine, which 
increases [Ca2+]i but is not known to activate PKC, 
also produced functional protection in isolated rat 
hearts. Furthermore, the mechanism by which exoge- 
nous Ca 2+ activates PKC remains unknown. It is 
possible that increasing [Ca2+]o increases [Ca2+]i by 
either calcium-induced-calcium release, voltage-oper- 
ated channels, or both, and that this increase in [Ca2+]i 
is sufficient stimulus to activate PKC. 
The ultimate benefit of preischemic induction of 
endogenous functional protection relates to its clin- 
ical applicability. Transient ischemia, which is a 
potent protective stimulus in animals, is less appeal- 
7 8 6 Meldrum et aL 
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ing clinically. Because CaCl 2 is both clinically acces- 
sible and acceptable, stimulating PKC-mediated 
myocardial functional protection with preischemic 
CaC12 infusion may even provide a means of en- 
hancing cardiac function after transplantation a d 
bypass operations. It must be emphasized, however, 
that these studies were performed with normal rat 
hearts. Both the salutary and the deleterious effects 
of Ca 2+ preconditioning of diseased human ventri- 
cles remain to be determined. 
We thank Drs. David A. Fullerton, James M. Brown, 
Robert C. McIntyre, Jr., and Xianzhong Meng for their 
insightful criticisms and suggestions; Dr. Daniel Chan for 
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for suggestions and expert echnical assistance. 
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